Extensive eosinophil degranulation and peroxidase-mediated oxidation of airway proteins do not occur in a mouse ovalbumin-challenge model of pulmonary inflammation

被引:98
作者
Denzler, KL
Borchers, MT
Crosby, JR
Cieslewicz, G
Hines, EM
Justice, JP
Cormier, SA
Lindenberger, KA
Song, W
Wu, WJ
Hazen, SL
Gleich, GJ
Lee, JJ
Lee, NA
机构
[1] Mayo Clin, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA
[2] Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA
[3] Mayo Clin, Dept Immunol, Allerg Dis Res Lab, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Med, Allerg Dis Res Lab, Rochester, MN 55905 USA
关键词
D O I
10.4049/jimmunol.167.3.1672
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Paradigms of eosinophil effector function in the lungs of asthma patients invariably depend on activities mediated by cationic proteins released from secondary granules during a process collectively referred to as degranulation. In this study, we generated knockout mice deficient for eosinophil peroxidase (EPO) to assess the role(s) of this abundant secondary granule protein in an OVA-challenge model. The loss of EPO had no effect on the development of OVA-induced pathologies in the mouse. The absence of phenotypic consequences in these knockout animals extended beyond pulmonary histopathologies and airway changes, as EPO-deficient animals also displayed OVA-induced airway hyperresponsiveness after provocation with methacholine. In addition, EPO-mediated oxidative damage of proteins (e.g., bromination of tyrosine residues) recovered in bronchoalveolar lavage from OVA-treated wild-type mice was <10% of the levels observed in bronchoalveolar lavage recovered from asthma patients. These data demonstrate that EPO activities are inconsequential to the development of allergic pulmonary pathologies in the mouse and suggest that degranulation of eosinophils recruited to the lung in this model does not occur at levels comparable to those observed in humans with asthma.
引用
收藏
页码:1672 / 1682
页数:11
相关论文
共 75 条
[1]  
BUTTERWORTH AE, 1993, HDB IMMUNOPHARMACOLO, P119
[2]   DUAL FUNCTION OF EOSINOPHILS IN PATHOGENESIS AND PROTECTIVE IMMUNITY AGAINST PARASITES [J].
CAPRON, M .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 1992, 87 :83-89
[3]  
CARLSON MGC, 1985, J IMMUNOL, V134, P1875
[4]   ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE [J].
CHIRGWIN, JM ;
PRZYBYLA, AE ;
MACDONALD, RJ ;
RUTTER, WJ .
BIOCHEMISTRY, 1979, 18 (24) :5294-5299
[5]   Mouse eosinophil-associated ribonucleases: a unique subfamily expressed during hematopoiesis [J].
Cormier, SA ;
Larson, KA ;
Yuan, SB ;
Mitchell, TL ;
Lindenberger, K ;
Carrigan, P ;
Lee, NA ;
Lee, JJ .
MAMMALIAN GENOME, 2001, 12 (05) :352-361
[6]  
DeKruyff R H, 1993, Semin Immunol, V5, P421, DOI 10.1006/smim.1993.1048
[7]   Eosinophil major basic protein-1 does not contribute to allergen-induced airway pathologies in mouse models of asthma [J].
Denzler, KL ;
Farmer, SC ;
Crosby, JR ;
Borchers, M ;
Cieslewicz, G ;
Larson, KA ;
Cormier-Regard, S ;
Lee, NA ;
Lee, JJ .
JOURNAL OF IMMUNOLOGY, 2000, 165 (10) :5509-5517
[8]  
DVORAK AM, 1991, AM J PATHOL, V138, P69
[9]   Human eotaxin represents a potent activator of the respiratory burst of human eosinophils [J].
Elsner, J ;
Hochstetter, R ;
Kimmig, D ;
Kapp, A .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (08) :1919-1925
[10]   Cytolysis and piecemeal degranulation as distinct modes of activation of airway mucosal eosinophils [J].
Erjefält, JS ;
Andersson, M ;
Greiff, L ;
Korsgren, M ;
Gizycki, M ;
Jeffery, PK ;
Persson, GA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (02) :286-294